Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 1050

Next Previous
Drug Profile

FT 1050

Alternative Names: 16, 16 dimethyl-prostaglandin E2; dmPGE2; FT1050; ProHema; ProHema-CB; Prostaglandin E2 - Fate Therapeutics

Latest Information Update: 02 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Childrens Hospital Boston; Massachusetts General Hospital
  • Developer Fate Therapeutics
  • Class Antineoplastics; Chemoprotectants; Prostaglandins; Small molecules
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stem cell mobilisation

Most Recent Events

  • 11 Apr 2016 Fate Therapeutics terminates a phase-I trial in Stem cell mobilisation (In infants, In children, In adolescents with haematological malignancies) in USA (IV) (NCT02354417)
  • 11 Apr 2016 Fate Therapeutics terminates a phase I trial for Stem cell mobilisation (in paediatric patients with metabolic disorders) in USA (NCT02354443)
  • 03 Mar 2016 Discontinued - Phase-I for Stem cell mobilisation (In adolescents, In children, In infants) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top